Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | GAPDH | P04406 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | STAT6 | P42226 | 1/20 | 0.55 |
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.55 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066601 | 1.00 | AHCY (0.63) | AHCYADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL12642436 | 1.00 | AHCY (0.63) | AHCYADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL8913539 | 1.00 | AHCY (0.63) | AHCYADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL8913548 | 1.00 | AHCY (0.63) | AHCYADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL8912042 | 0.84 | AHCY (0.62) | AHCYADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL9445334 | 0.84 | AHCY (0.62) | AHCYADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL8912036 | 0.84 | AHCY (0.62) | AHCYADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL2911889 | 0.84 | AHCY (0.44) | AHCYADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL9445342 | 0.83 | AHCY (0.67) | AHCYADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL8913115 | 0.83 | AHCY (0.67) | AHCYADORA2BADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994001117-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | claimed |
| EP-0491793-A4 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | — | 1993-03-03 | — | — | EP | claimed |
| EP-0491793-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-01 | — | — | EP | claimed |
| WO-1991004033-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-04-04 | — | — | WO | claimed |
| US-20080058276-A1 | Cis, trans isomerization; serine, threonine profile; therapy, prevention neurodegenerative disorders | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-1994001117-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| EP-0491793-A4 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | — | 1993-03-03 | — | — | EP | disclosed |
| EP-0491793-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1991004033-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058276-A1 | Cis, trans isomerization; serine, threonine profile; therapy, prevention neurodegenerative disorders | APP, PSEN1, PIN1 | AHCY 509/4885ADORA2B 3567/4885ADORA3 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.